MCP-1 serves as a significant inflammatory marker, and recent research has correlated heightened MCP-1 levels with the severity of Parkinson’s disease, as well as a possible association with non-motor symptoms, such as depression and cognitive impairment [72,73]. Here, CCL2 is linked to Cognitive impairment.